IRD
Opus Genetics, Inc.
NASDAQ: IRD · HEALTHCARE · BIOTECHNOLOGY
$4.99
-6.90% today
Updated 2026-05-08
Market cap
$356.30M
P/E ratio
—
P/S ratio
25.10x
EPS (TTM)
$-0.80
Dividend yield
—
52W range
$1 – $6
Volume
0.9M
Opus Genetics, Inc. (IRD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $589000.00 | $39.85M | $19.05M | $10.99M | $14.20M |
| Revenue growth (YoY) | — | — | — | +6665.7% | -52.2% | -42.3% | +29.1% |
| Cost of revenue | — | $8000.00 | $4000.00 | $4000.00 | $6000.00 | $10000.00 | $53000.00 |
| Gross profit | — | $-8000.00 | $589000.00 | $39.85M | $19.05M | $10.99M | $14.14M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 99.6% |
| R&D | $2.37M | $6.65M | $15.17M | $14.36M | $17.65M | $26.85M | $30.81M |
| SG&A | $1.82M | $2.82M | $8.12M | $7.27M | $11.96M | $18.21M | $21.98M |
| Operating income | $-4.19M | $-19.97M | $-22.70M | $18.23M | $-10.56M | $-62.07M | $-38.60M |
| Operating margin | — | — | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| EBITDA | $-4.76M | $-17.77M | $-56.69M | $18.22M | $-9.97M | $-57.52M | $-38.60M |
| EBITDA margin | — | — | -9624.3% | 45.7% | -52.3% | -523.3% | -271.9% |
| EBIT | $-4.76M | $-17.77M | $-56.69M | $18.21M | $-9.97M | $-57.53M | $-38.65M |
| Interest expense | $1.41M | $6.85M | $2000.00 | $9000.00 | $1.33M | $0.00 | $1.47M |
| Income tax | — | — | — | $315000.00 | $12000.00 | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 1.7% | -0.1% | 0.0% | 0.0% |
| Net income | $-6.17M | $-24.62M | $-56.69M | $17.89M | $-9.99M | $-57.53M | $-49.59M |
| Net income growth (YoY) | — | -299.1% | -130.3% | +131.6% | -155.8% | -476.1% | +13.8% |
| Profit margin | — | — | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |